List of Excipients in Branded Drug AMINOPHYLLINE

Generic Drugs Containing AMINOPHYLLINE

Company	Ingredient	NDC	Excipient
Hospira Inc	aminophylline	0409-5921	ETHYLENEDIAMINE
Hospira Inc	aminophylline	0409-5921	WATER
HF Acquisition Co LLC DBA HealthFirst	aminophylline	51662-1204	ETHYLENEDIAMINE
HF Acquisition Co LLC DBA HealthFirst	aminophylline	51662-1204	WATER
HF Acquisition Co LLC DBA HealthFirst	aminophylline	51662-1341	ETHYLENEDIAMINE

What are the Most Frequently-Used Excipients in AMINOPHYLLINE?

# Of NDCs	Excipient
7	ETHYLENEDIAMINE
7	WATER

Aminophylline Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 17, 2026

Aminophylline is an established, low-cost bronchodilator composed of theophylline and ethylenediamine. Its commercial value is limited in routine adult asthma and COPD because inhaled therapies have displaced oral and injectable methylxanthines. Opportunities remain in parenteral supply, hospital-use products, pediatric dosage forms, modified-release delivery, regional markets, and excipient-enabled stability improvements.

The strongest product strategy is not a new aminophylline molecule. It is a controlled formulation that manages pH, precipitation, dose uniformity, tolerability, and release performance while preserving a low-cost manufacturing process.

What is aminophylline and how does its formulation differ from theophylline?

Aminophylline is a 2:1 molar complex of theophylline and ethylenediamine. Ethylenediamine increases theophylline’s aqueous solubility, allowing injectable products that would be difficult to formulate using theophylline alone. Theophylline remains the pharmacologically active component.

Attribute	Aminophylline	Theophylline
Active component	Theophylline complexed with ethylenediamine	Theophylline
Main formulation advantage	Higher aqueous solubility	Simpler solid-state composition
Common dosage forms	Injection, oral tablets and capsules in some markets	Immediate-release and extended-release oral products
Key formulation risk	pH sensitivity, precipitation, ethylenediamine compatibility	Low aqueous solubility, variable release
Therapeutic risk	Narrow therapeutic index	Narrow therapeutic index
Commercial position	Mature generic product	Mature generic product with broader historical product diversity

FDA labeling identifies aminophylline injection as a prescription bronchodilator used for reversible airflow obstruction. The product is administered intravenously or intramuscularly, with dosing adjusted to clinical response and serum theophylline concentrations in appropriate patients (DailyMed, 2024).

What excipients are most important in aminophylline formulations?

The excipient platform depends on the dosage form. Parenteral products prioritize pH, clarity, sterility, and chemical stability. Oral products prioritize compressibility, dose uniformity, dissolution control, and patient acceptability.

Parenteral excipient strategy

Aminophylline injection is typically formulated as an aqueous solution with an alkaline pH. The pH is necessary to maintain solubility but increases the risk of local irritation and incompatibility with acidic admixtures.

Relevant excipient functions include:

Formulation function	Candidate excipient category	Commercial purpose
Vehicle	Water for Injection	Primary solvent
pH control	Sodium hydroxide or compatible alkaline adjuster	Maintains aminophylline solubility
Tonicity	Sodium chloride or other compatible tonicity agent	Improves administration tolerability
Chelation or metal control	Product-specific chelator, where justified	Limits trace-metal degradation
Container protection	Low-extractable elastomer and compatible glass or polymer	Controls adsorption and leachables
Antimicrobial preservation	Preservative only where the presentation and route permit	Supports multidose packaging

Aminophylline injection should not be treated as a conventional buffered injectable. Acidic buffers can reduce the solubility of the theophylline component and create precipitation risk. Compatibility with co-administered drugs and infusion fluids is a major product-development issue. Product labeling commonly warns against mixing aminophylline with incompatible solutions or drugs, particularly acidic materials.

The highest-value parenteral excipient work is therefore narrow and practical:

1. Maintain a stable alkaline pH throughout shelf life.
2. Prevent visible or subvisible precipitation after dilution.
3. Limit container interaction and extractables.
4. Support rapid visual inspection.
5. Demonstrate compatibility with hospital dilution practices.

A preservative-free, single-dose presentation may have stronger hospital value than a multidose format because it reduces preservative exposure and simplifies compatibility control. A ready-to-administer or pharmacy-ready presentation could compete on workflow and medication-error reduction, although the commercial case depends on hospital purchasing and packaging costs.

Solid oral excipient strategy

For immediate-release aminophylline tablets, the formulation must deliver consistent theophylline exposure despite a relatively low dose and narrow therapeutic index. Useful excipient categories include:

• Microcrystalline cellulose for compactibility.
• Lactose or mannitol as fillers, subject to compatibility and moisture control.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as disintegrants.
• Povidone or hydroxypropyl cellulose as binders.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate or another lubricant at controlled concentration.
• Film-coating polymers for handling, taste, and moisture protection.

The main development risk is excessive formulation variability. Over-lubrication can slow dissolution. Differences in particle size, density, and blend segregation can affect dose uniformity. A robust process should control the particle-size distribution of aminophylline, mixing order, lubrication time, compression force, and tablet porosity.

Modified-release strategy

Modified-release aminophylline or theophylline products can reduce dosing frequency and smooth peak-to-trough exposure. The formulation can use hydrophilic matrix polymers such as hypromellose or hydrophobic barriers such as ethylcellulose. Multiparticulate capsules, coated pellets, and osmotic systems are other options.

A modified-release product needs more than a dissolution profile at a single pH. It should address:

• Alcohol-induced dose dumping.
• Food effects.
• Transit-time variability.
• Dose proportionality.
• Tablet splitting or crushing.
• Interpatient exposure variability.
• Conversion from immediate-release therapy.

Theophylline has historically been available in extended-release products, but aminophylline-specific opportunities may be narrower because the market often uses theophylline as the active pharmaceutical ingredient. A new aminophylline extended-release product would need a clear clinical or operational advantage over existing theophylline products.

What manufacturing and excipient barriers affect aminophylline products?

Aminophylline’s manufacturing barriers are manageable but commercially important.

Solid-state and blend control

Theophylline exists in different solid forms, including anhydrous and hydrate forms. Water activity, drying conditions, milling, and storage can affect solid-state behavior. Aminophylline’s ethylenediamine component also creates a formulation environment that requires control of moisture and composition.

Critical manufacturing controls include:

• Raw-material identity and assay.
• Theophylline-to-ethylenediamine stoichiometry.
• Water content.
• Particle-size distribution.
• Blend uniformity.
• Granule moisture.
• Compression behavior.
• Dissolution across relevant pH conditions.

Injectable compatibility

Injectables face tighter operational constraints. The manufacturer must control solution pH, assay, degradation products, particulate matter, sterility, endotoxin, container closure integrity, and visual appearance. The product must remain stable during storage and, where labeled, after dilution.

The most defensible formulation claims are likely to focus on a defined pH range, a specific solvent and tonicity system, container compatibility, or a stability profile. Broad claims covering any aqueous aminophylline solution would face a high risk of prior-art and obviousness challenges.

What is the FDA regulatory status of aminophylline?

Aminophylline is a legacy prescription drug used primarily in hospital and selected outpatient settings. FDA-regulated products may be marketed under approved new drug applications, abbreviated new drug applications, or older regulatory pathways depending on the product and its history.

The FDA’s Orange Book identifies approved drug products and therapeutic-equivalence information, but the commercial status of individual aminophylline presentations can change as manufacturers discontinue products or update marketing status. The Orange Book does not itself establish that every historically listed product remains commercially available (FDA, 2025a).

DailyMed provides current labeling for marketed products and is the more useful source for formulation-specific excipient information. Label review should distinguish between:

• Aminophylline injection.
• Immediate-release oral aminophylline products.
• Extended-release theophylline products.
• Products that contain theophylline but not aminophylline.

The FDA Inactive Ingredient Database can support excipient precedent, but it does not by itself establish approval for a new route, concentration, or dosage form (FDA, 2025b).

What patents protect aminophylline products?

The core aminophylline composition is old and is not a realistic platform for new exclusivity. The commercial patent opportunity lies in formulation, delivery, packaging, manufacturing, or a new therapeutic use.

Patent category	Expected commercial relevance	Strength of typical opportunity
Core aminophylline composition	Historical only	Very weak for new exclusivity
Immediate-release tablet composition	Possible	Low to moderate
Extended-release matrix or multiparticulate system	Possible	Moderate if performance is distinctive
Injectable pH and compatibility system	Possible	Moderate if narrowly claimed and well supported
Ready-to-use hospital presentation	Possible	Moderate, with packaging and method claims
New indication	Possible but clinically demanding	Variable
Manufacturing process	Possible	Moderate if process materially improves quality or cost
Container-closure system	Possible	Usually narrow
Digital dosing or monitoring platform	Limited drug patent value	May support separate device or software rights

A new patent estate would need claims directed to measurable technical features. Examples include a defined dissolution pattern, a specific particle-size range, a stable pH window, reduced precipitation after dilution, a particular polymer architecture, or a demonstrated reduction in exposure variability.

Patent strength would depend on whether the claimed feature is necessary to achieve a clinically relevant result. Claims limited to routine excipient substitutions, ordinary buffers, or standard tablet fillers would face substantial obviousness risk under U.S. patent law.

When does aminophylline lose exclusivity?

Aminophylline’s original composition and early product exclusivities expired decades ago. The current competitive issue is not loss of an original patent term. It is whether a specific marketed presentation has a later formulation patent, regulatory exclusivity, or supply position.

Exclusivity type	Current strategic assessment
Original composition patent	Expired
Original FDA approval exclusivity	Expired
Standard generic product exclusivity	Generally not a barrier
Pediatric exclusivity	Not expected to create a current broad barrier
Orphan exclusivity	Not applicable to the established general use
Formulation patent	Product-specific and requires current patent verification
Method-of-use patent	Narrow and indication-specific

A Paragraph IV challenge would matter only if an active, listed patent covered a currently approved product. For mature aminophylline products, the more common entry pathway is generic competition based on expired protection or product discontinuation, not a high-value patent dispute.

What Orange Book and Paragraph IV issues affect aminophylline?

The relevant analysis is product-specific. A company cannot infer Orange Book exposure from the active ingredient alone. It must examine the exact strength, dosage form, route, reference-listed drug, and listed patents.

Key questions include:

• Is the reference product currently listed as marketed?
• Does the Orange Book list any patents for the product?
• Are the patents formulation, method-of-use, or drug-substance patents?
• Has any patent expired or been delisted?
• Would an ANDA applicant need a Paragraph IV certification?
• Is a 30-month stay possible under the listed patent framework?

For an old generic injectable, the practical barriers are often manufacturing validation, sterile-facility capacity, supply reliability, and hospital contracting rather than Paragraph IV litigation. No broad, current patent barrier should be assumed for aminophylline without a product-level Orange Book and patent-record review.

Which companies are challenging aminophylline patents?

Aminophylline does not have the litigation profile of newer oncology, immunology, or rare-disease products. Generic manufacturers may compete through ANDA filings, abbreviated approvals, or commercial supply agreements without public patent litigation.

The competitive field can include:

• Generic injectable manufacturers.
• Contract manufacturers with sterile-fill capacity.
• Regional pharmaceutical companies.
• Hospital suppliers.
• Branded companies selling alternative methylxanthine products.
• Manufacturers of theophylline extended-release products.

Public litigation risk is more likely to arise from product quality, labeling, supply, or antitrust issues than from a major active patent dispute. Any current Paragraph IV or settlement conclusion must be tied to a named reference product and verified against court and FDA records.

How strong is the aminophylline patent estate?

The base aminophylline estate is weak because the active ingredient, conventional dosage forms, and broad therapeutic use are mature. A new formulation estate can be commercially useful but is unlikely to support premium pricing by itself.

Stronger claim themes

• Demonstrated reduction in precipitation after dilution.
• Improved stability under defined temperature and light conditions.
• Controlled release that reduces clinically relevant exposure variability.
• A specific pediatric dosage form with superior dose flexibility.
• A ready-to-use presentation that improves preparation safety.
• A manufacturing process that produces a defined solid form or impurity profile.

Weaker claim themes

• Substitution of one routine filler for another.
• Conventional alkaline pH adjustment without unexpected results.
• Generic use of hypromellose or ethylcellulose.
• Broad claims to all aminophylline solutions.
• Claims that merely restate an established dose or route.

What commercial opportunities exist for aminophylline excipients?

The strongest opportunities are operational rather than premium branded therapy.

Opportunity	Customer	Value proposition	Commercial outlook
Preservative-free injection	Hospitals and pharmacies	Lower preservative exposure and simpler single-dose use	Moderate
Ready-to-use IV presentation	Hospitals	Fewer preparation steps and lower compounding burden	Moderate to strong
Stable diluted infusion	Hospitals	Better compatibility and reduced waste	Moderate
Pediatric oral liquid	Pediatric and hospital markets	Flexible dosing and improved administration	Moderate
Taste-masked oral solid or liquid	Caregivers and patients	Better adherence	Moderate
Extended-release product	Outpatient patients	Less frequent dosing	Limited to moderate
Low-cost regional generic	Emerging markets	Access and supply continuity	Moderate
Dual-source excipient platform	Manufacturers	Lower supply-chain risk	Strong as a B2B opportunity

Excipient suppliers may find better economics in platform technologies that apply to aminophylline and other alkaline, poorly soluble, narrow-therapeutic-index drugs. Examples include low-peroxide polymers, high-purity injectable excipients, controlled-particle-size fillers, and container systems with lower extractables.

How does aminophylline compare with competing bronchodilator products?

Aminophylline competes against inhaled beta agonists, inhaled antimuscarinics, inhaled corticosteroids, and systemic theophylline products. These alternatives generally have stronger current clinical positioning.

Product class	Relative advantage over aminophylline	Aminophylline weakness
Inhaled beta agonists	Rapid targeted bronchodilation	Systemic aminophylline exposure
Inhaled antimuscarinics	Established COPD use	Limited role for aminophylline
Inhaled corticosteroids	Anti-inflammatory treatment	Aminophylline does not replace them
Theophylline extended release	Familiar oral delivery	Similar therapeutic-index concerns
Aminophylline injection	Parenteral hospital option	Monitoring, interactions, and adverse-effect risk

Aminophylline’s defensible market is therefore concentrated in situations where injectable administration, cost, or local availability matters. Excipient innovation should target those settings instead of attempting to reposition aminophylline as a first-line chronic respiratory therapy.

What generic entry risks exist for aminophylline?

Generic entry risk is high for conventional aminophylline products because the active ingredient is old and alternative suppliers can use established excipient systems. The principal risks are:

1. Price erosion in standard injectable products.
2. Hospital tender substitution.
3. Supply disruption from sterile manufacturing failures.
4. Rapid switching to theophylline or inhaled therapies.
5. Limited reimbursement for premium formulation variants.
6. Difficulty differentiating a routine tablet or injection.

A differentiated product can reduce substitution risk through hospital workflow benefits, documented dilution compatibility, pediatric dosing flexibility, or superior shelf life. The commercial premium must be tied to a measurable purchasing benefit.

What is the best aminophylline product-development strategy?

The most credible strategy is a staged portfolio:

Near-term product

Develop a preservative-free, single-dose injectable presentation with robust pH control, clear compatibility instructions, low particulate burden, and packaging designed for hospital use.

Mid-term product

Develop a pediatric oral liquid or dispersible dosage form with dose flexibility, taste control, and validated uniformity across the dosing range.

Higher-risk product

Develop an extended-release aminophylline or theophylline product only if pharmacokinetic data show a meaningful reduction in exposure variability or dosing burden.

The formulation package should include forced-degradation studies, precipitation testing after dilution, container-closure evaluation, extractables and leachables, dissolution testing, bioequivalence planning, and stability under relevant shipping conditions. ICH quality guidance supports a risk-based development framework linking critical material attributes and process parameters to product performance (ICH, 2009).

Key Takeaways

• Aminophylline is a mature generic drug with expired core composition exclusivity.
• The excipient challenge is controlling alkaline pH, precipitation, compatibility, dose uniformity, and release.
• Parenteral hospital products offer the clearest commercial opportunity.
• Preservative-free and ready-to-use presentations can create practical differentiation.
• Pediatric liquids and flexible-dose products are more attractive than conventional adult tablets.
• Extended-release products face competition from established theophylline formulations.
• A new patent estate should claim measurable formulation performance, not routine excipient selection.
• Current Orange Book, Paragraph IV, and litigation exposure is product-specific.
• Generic entry risk is high for undifferentiated aminophylline products.
• The best B2B opportunity may be excipient and container platforms that also apply to other narrow-therapeutic-index drugs.

FAQs

Is aminophylline still commercially relevant?

Yes, primarily as a hospital injectable and in selected regional or specialty markets. Its chronic outpatient role is limited by inhaled therapies and theophylline alternatives.

Which excipients improve aminophylline injection stability?

The formulation normally depends on Water for Injection and controlled alkalinity. Tonicity agents and other excipients must be selected through compatibility and stability studies because acidic conditions can promote precipitation.

Can a new aminophylline formulation receive patent protection?

Yes, but protection would most likely require a novel and non-obvious formulation, manufacturing process, delivery system, or demonstrated performance advantage.

Is aminophylline a good candidate for a pediatric liquid?

It can be, particularly where flexible dosing and hospital access are important. The main development issues are taste, dose uniformity, chemical stability, and safe measurement by caregivers.

Does aminophylline have biosimilar competition?

No. Aminophylline is a small-molecule drug, so competitors use generic-drug pathways rather than biosimilar pathways.

References

1. DailyMed. (2024). Aminophylline injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. https://www.ich.org/

3. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

4. U.S. Food and Drug Administration. (2025b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2011). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/regulatory-information/search-fda-guidance-documents